What SEC filings does Alkermes plc submit to the SEC?

Alkermes plc (ALKS) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ALKS?

A Form 4 for ALKS discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Alkermes plc?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ALKS?

The 10-K is Alkermes plc's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ALKS SEC filings directly on EDGAR?

You can view all historical Alkermes plc filings on the SEC EDGAR company page for ALKS. Each filing card on this page links directly to the original SEC document.

How often does Alkermes plc file with the SEC?

Alkermes plc files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ALKS shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

ALKS SEC Filing News — Alkermes plc

Latest SEC filings for Alkermes plc (ALKS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-09.

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. …

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $7.1B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for ALKS currently lean bearish. Of the 20 filing records displayed, 6 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

ALKS Filing Activity Snapshot 2026-08-03 — 2026-10-09

Insider Transactions (Form 4)

0 buys vs 6 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$2.24M

snyderman nancy lynn MD (Director) · 2026-08-03

44,472 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Alkermes plc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 6 open-market sale, 2 compensation award and 1 option exercise. 6 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×6: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×2: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Form 4 Option exercise Tax / Compensation Filing 2026-10-09

ALKS insider Form 4 filed for equity award, exercise, or tax withholding

Reed Joshua (SVP, Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	9,164	—	—
`F`	Tax withholding on vested shares	4,069	$40.11	$163.2K
`M`	Option exercise derivative · Restricted Stock Unit Award	9,164	—	—

Filing: Form 4 (Insider Transaction) Insider: Reed Joshua (SVP, Chief Financial Officer) Shares: 13,233

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-09

ALKS insider Form 4 filed for equity award, exercise, or tax withholding

Whitaker Anne Clem (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Restricted Stock Unit Award	7,239	—	—
`A`	Compensation award derivative · Non Qualified Stock Option (Right to Buy)	17,998	—	—

Filing: Form 4 (Insider Transaction) Insider: Whitaker Anne Clem (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-02

ALKS insider Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares (~$83.5K)

Gaffin David Joseph, listed as EVP, CLO, Alkermes, Inc. at Alkermes plc., reported an open-market sale of 2,034 ALKS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,034	$41.03	$83.5K

Filing: Form 4 (Insider Transaction) Insider: Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) Shares: 2,034 Est. Value: $83.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-03

ALKS insider Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares (~$97.7K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,034	$48.01	$97.7K

Filing: Form 4 (Insider Transaction) Insider: Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) Shares: 2,034 Est. Value: $97.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-01

ALKS insider Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares (~$422.9K)

Hopkinson Craig C., listed as EVP R&D, Chief Medical Officer at Alkermes plc., reported an open-market sale of 9,000 ALKS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	5,000	$24.59	$123.0K
`S`	Open-market sale	9,000	$46.99	$422.9K
`M`	Option exercise derivative · Employee Stock Option (Right to Buy)	5,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Hopkinson Craig C. (EVP R&D, Chief Medical Officer) Shares: 9,000 Est. Value: $422.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-17

ALKS insider Nichols Christian Todd (SVP, Chief Commercial Officer) sold 7,576 shares (~$372.9K)

Nichols Christian Todd, listed as SVP, Chief Commercial Officer at Alkermes plc., reported an open-market sale of 7,576 ALKS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	6,912	$49.19	$340.0K
`S`	Open-market sale	664	$49.65	$33.0K

Filing: Form 4 (Insider Transaction) Insider: Nichols Christian Todd (SVP, Chief Commercial Officer) Shares: 7,576 Est. Value: $372.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-07

ALKS insider Form 4 filed for equity award, exercise, or tax withholding

Jackson Blair Curtis (Director, President & CEO, Alkermes plc) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (Right to Buy)	93,229	—	—
`A`	Compensation award derivative · Employee Stock Option (Right to Buy)	124,305	—	—

Filing: Form 4 (Insider Transaction) Insider: Jackson Blair Curtis (Director, President & CEO, Alkermes plc)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-03

ALKS insider snyderman nancy lynn MD (Director) sold 44,472 shares (~$2.24M)

snyderman nancy lynn MD, listed as Director at Alkermes plc., reported an open-market sale of 44,472 ALKS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	27,948	$46.72	$1.31M
`M`	Option exercise	16,524	$46.72	$772.0K
`S`	Open-market sale	44,472	$50.35	$2.24M
`M`	Option exercise derivative · Non Qualified Stock Option (Right to Buy)	27,948	—	—
`M`	Option exercise derivative · Non Qualified Stock Option (Right to Buy)	16,524	—	—

Filing: Form 4 (Insider Transaction) Insider: snyderman nancy lynn MD (Director) Shares: 44,472 Est. Value: $2.24M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-03

ALKS insider Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares (~$437.2K)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	104	$19.34	$2.0K
`M`	Option exercise	4,896	$24.59	$120.4K
`S`	Open-market sale	9,000	$48.58	$437.2K
`M`	Option exercise derivative · Employee Stock Option (Right to Buy)	104	—	—
`M`	Option exercise derivative · Employee Stock Option (Right to Buy)	4,896	—	—

Filing: Form 4 (Insider Transaction) Insider: Hopkinson Craig C. (EVP R&D, Chief Medical Officer) Shares: 9,000 Est. Value: $437.2K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 7 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Alkermes plc has 7 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-02

ALKS Form 144 filed for proposed insider sale

An insider at Alkermes plc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.